Glaucoma is one of the leading causes of blindness globally, and is characterized by loss of retinal ganglion cells (RGCs). Because vision loss in glaucoma is not reversible, therapeutic interventions early in disease are highly desirable. However, owing to the current limitations in evaluating glaucomatous neurodegeneration, it is challenging to monitor the disease severity and progression objectively, and to design rational therapeutic strategies accordingly. Therefore, there is a clear need to identify quantifiable molecular biomarkers of glaucomatous neurodegeneration. As such, in our opinion, molecular biomarker(s) that specifically reflect stress or death of RGCs, and which correlate with disease severity, progression, and response to therapy, are highly desirable.

Original languageEnglish
Pages (from-to)7-17
Number of pages11
JournalTrends in Molecular Medicine
Issue number1
StatePublished - Jan 2018


  • aqueous humor
  • biomarker
  • glaucoma
  • growth differentiation factor 15 (GDF15)
  • neurodegeneration
  • retinal ganglion cell


Dive into the research topics of 'Monitoring Neurodegeneration in Glaucoma: Therapeutic Implications'. Together they form a unique fingerprint.

Cite this